To the editor

New England Journal of Medicine

Volumn 375, Issue 26, 2016, Pages 2610-

  Brust, James C M ^a   Shah, N Sarita ^b   Gandhi, Neel R ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM CULTURE; DRUG TREATMENT FAILURE; HEALTH CARE COST; HUMAN; LETTER; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RELAPSE; TUBERCULOSIS RAPID TEST; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85007347070     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1613123     Document Type: Letter

References (4)

1. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva: World Health Organization, 2013.
2. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-5.
3. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
4. Mitnick CD, White RA, Lu C, et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J 2016; 48: 1160-70.